Lista de obras -

A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer ⬇️

artículo científico publicado el 23 de diciembre de 2010

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry

artículo científico publicado en 2010

A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas ⬇️

artículo científico publicado el 18 de marzo de 2011

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer

artículo científico publicado en 2013

Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers

artículo científico publicado en 2011

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

artículo científico publicado en 2013

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

artículo científico publicado en 2016

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer ⬇️

artículo científico publicado el 12 de octubre de 2010

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

artículo científico publicado en 2011

An X chromosome gene, WTX, is commonly inactivated in Wilms tumor

artículo científico publicado en 2007

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

artículo científico publicado en 2010

Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses

artículo científico publicado en 2012

BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults

artículo científico publicado en 2013

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications

artículo científico publicado en 2011

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation ⬇️

artículo científico publicado el 23 de noviembre de 2010

Biliary Adenofibroma of Liver: Morphology, Tumor Genetics, and Outcomes in 6 Cases

artículo científico publicado en 2017

Characterization and analysis of human chordoma cell lines

artículo científico publicado en 2010

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma

artículo científico publicado en 2014

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations

artículo científico publicado en 2015

Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma

artículo científico publicado en 2014

Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma

artículo científico publicado en 2009

Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer.

artículo científico publicado en 2016

Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma.

artículo científico publicado en 2009

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

artículo científico publicado en 2014

Decreased survival in EGFR gene amplified vulvar carcinoma

artículo científico publicado en 2008

Dendritic Cells in Kidney Transplant Biopsy Samples Are Associated with T Cell Infiltration and Poor Allograft Survival

artículo científico publicado en 2015

Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

artículo científico publicado en 2015

Detection of large-scale variation in the human genome

artículo científico publicado en 2004

Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression

artículo científico publicado en 2010

EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas

artículo científico publicado en 2011

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

artículo científico publicado en 2011

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma

artículo científico publicado en 2016

Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability

artículo científico publicado en 2009

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

artículo científico publicado en 2011

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

artículo científico publicado en 2008

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

artículo científico publicado en 2011

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

artículo científico publicado en 2015

High lung shunt fraction in colorectal liver tumors is associated with distant metastasis and decreased survival

artículo científico publicado en 2014

Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas

artículo científico publicado en 2012

Inactivation of the tumor suppressor WTX in a subset of pediatric tumors

scientific article published on 05 November 2013

Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer

artículo científico publicado en 2015

Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment

artículo científico publicado en 2007

MET Exon 14 Skipping in Non-Small Cell Lung Cancer.

artículo científico publicado en 2016

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

artículo científico publicado en 2011

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

artículo científico publicado en 2012

Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer

artículo científico publicado en 2015

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features

artículo científico publicado en 2007

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

artículo científico publicado en 2015

NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

artículo científico publicado en 2011

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

artículo científico publicado en 2014

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

artículo científico publicado en 2020

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

artículo científico publicado en 2011

Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.

artículo científico publicado en 2009

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

artículo científico publicado en 2010

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma

artículo científico publicado en 2015

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response

artículo científico publicado en 2012

Prospective, high-throughput molecular profiling of human gliomas

artículo científico publicado en 2012

Pulmonary adenocarcinoma mutation profile in smokers with smoking-related interstitial fibrosis

artículo científico publicado en 2014

ROS1 rearrangements define a unique molecular class of lung cancers

artículo científico publicado en 2012

Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification

artículo científico publicado en 2008

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor

artículo científico publicado en 2012

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

artículo científico publicado en 2010

Recurrent chromosomal copy number alterations in sporadic chordomas

artículo científico publicado en 2011

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

artículo científico publicado en 2016

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

artículo científico publicado en 2012

Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers

artículo científico publicado en 2011

Standardized decision support in next generation sequencing reports of somatic cancer variants

artículo científico

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

artículo científico publicado en 2014

The challenges posed by cancer heterogeneity

artículo científico publicado en 2012

The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma.

artículo científico publicado en 2011

Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis

artículo científico publicado en 2013

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib

artículo científico publicado en 2014

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

artículo científico publicado en 2009

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

artículo científico publicado en 2014

Lista de obras de

A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer ⬇️

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry

A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas ⬇️

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer

Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer ⬇️

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

An X chromosome gene, WTX, is commonly inactivated in Wilms tumor

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses

BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation ⬇️

Biliary Adenofibroma of Liver: Morphology, Tumor Genetics, and Outcomes in 6 Cases

Characterization and analysis of human chordoma cell lines

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations

Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma

Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma

Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer.

Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Decreased survival in EGFR gene amplified vulvar carcinoma

Dendritic Cells in Kidney Transplant Biopsy Samples Are Associated with T Cell Infiltration and Poor Allograft Survival

Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Detection of large-scale variation in the human genome

Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression

EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma

Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

High lung shunt fraction in colorectal liver tumors is associated with distant metastasis and decreased survival

Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas

Inactivation of the tumor suppressor WTX in a subset of pediatric tumors

Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer

Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment

MET Exon 14 Skipping in Non-Small Cell Lung Cancer.

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response

Prospective, high-throughput molecular profiling of human gliomas

Pulmonary adenocarcinoma mutation profile in smokers with smoking-related interstitial fibrosis

ROS1 rearrangements define a unique molecular class of lung cancers

Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

Recurrent chromosomal copy number alterations in sporadic chordomas

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers

Standardized decision support in next generation sequencing reports of somatic cancer variants

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

The challenges posed by cancer heterogeneity

The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma.

Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs